SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)	3 Months Ended		9 Months Ended
	Jul. 31, 2024 USD ($)	Jul. 31, 2023 USD ($)	Jul. 31, 2024 USD ($) Integer shares	Jul. 31, 2023 USD ($) Integer shares
Product Information [Line Items]
FDIC limits per institutions	$ 250,000		$ 250,000
Cash balances	343,000		343,000
Revenues	1,091,000	$ 1,221,000	3,376,000	$ 3,136,000
Research and development expense	75,000	335,000	$ 80,000	$ 938,000
Operating segment | Integer			1	1
Common Shares Issuable Upon The Exercise Of Options And Warrants [Member]
Product Information [Line Items]
Antidilutive securities excluded from computation of earnings per share | shares			3,787,527	2,549,000
Common Shares Issuable Upon The Exercise Of Ounvested Shares Of Restricted Stock [Member]
Product Information [Line Items]
Antidilutive securities excluded from computation of earnings per share | shares			182,500	250,000
Large Distributor [Member]
Product Information [Line Items]
Revenues	$ 178,000	$ 334,000	$ 570,000	$ 880,000
Large Distributor [Member] | Revenue Benchmark [Member] | Customer Concentration Risk [Member]
Product Information [Line Items]
Concentration percentage	16.30%	27.30%	16.80%	28.10%
Individual Medical Practice [Member]
Product Information [Line Items]
Revenues	$ 125,000		$ 382,000
Individual Medical Practice [Member] | Revenue Benchmark [Member] | Customer Concentration Risk [Member]
Product Information [Line Items]
Concentration percentage	10.20%		11.20%
Another Large Distributor [Member]
Product Information [Line Items]
Revenues			$ 418,000	$ 448,000
Another Large Distributor [Member] | Revenue Benchmark [Member] | Customer Concentration Risk [Member]
Product Information [Line Items]
Concentration percentage			12.30%	14.30%